Education
About Us
Working with TipRanks
Follow Us
GSEU - ETF AI Analysis
Top Page
Goldman Sachs ActiveBeta Europe Equity ETF (GSEU)
Rating:63Neutral
Price Target:―
Positive Factors
Solid Recent Performance
The ETF has shown steady gains over the past three months and year-to-date, indicating positive recent momentum.
Strong Leading Holdings
Several of the largest positions, such as ASML, Roche, Novartis, HSBC, Siemens, and Santander, have delivered strong or steady performance, helping support the fund’s returns.
Broad European Diversification
Holdings spread across major European markets and multiple sectors, including financials, industrials, health care, and consumer stocks, help reduce reliance on any single country or industry.
Negative Factors
Sector Concentration in Financials and Industrials
A large share of the portfolio is in financial and industrial companies, which can make the fund more sensitive to downturns in these areas.
Several Weak Top Holdings
Some key positions like AstraZeneca, SAP, Nestlé, and Shell have shown weaker recent performance, which can drag on overall returns if the trend continues.
Moderate Fund Size
With a relatively modest asset base, the ETF may be less liquid than larger funds, which could matter for investors trading bigger amounts.
GSEU vs. SPDR S&P 500 ETF (SPY)
AUM116.23M
RegionEurope
Expense Ratio0.25%
Beta0.67
IssuerGoldman Sachs
Inception DateMar 02, 2016
Dividend Yield2.73%
Asset ClassEquity
Index TrackedGoldman Sachs ActiveBeta Europe Equity
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume17,456
30 Day Avg. Volume16,339
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
51.72Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering348
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GSEU Summary
The Goldman Sachs ActiveBeta Europe Equity ETF (GSEU) is a fund that follows the Goldman Sachs ActiveBeta Europe Equity index, aiming to capture stock market opportunities across many European countries. It holds a wide mix of companies of different sizes and sectors, including well-known names like Nestlé, ASML, HSBC, and AstraZeneca. Someone might invest in this ETF to get broad, diversified exposure to European stocks in a single investment, with the potential for long-term growth. A key risk is that its value can rise or fall with the European stock market and economic conditions in that region.
How much will it cost me?The Goldman Sachs ActiveBeta Europe Equity ETF (Ticker: GSEU) has an expense ratio of 0.25%, meaning you’ll pay $2.50 per year for every $1,000 invested. This cost is lower than average for actively managed funds because it uses a systematic strategy to balance multiple factors, making it more efficient than many traditional active funds.
What would affect this ETF?The GSEU ETF, which focuses on European equities, could benefit from economic recovery in Europe, increased demand for healthcare and technology innovations, and stable financial sector performance, given its significant exposure to these areas. However, it may face challenges from rising interest rates, regulatory changes in Europe, or economic slowdowns that could negatively impact industrial and consumer sectors. Its diversified holdings across developed European markets provide some resilience against sector-specific risks.
GSEU Top 10 Holdings
GSEU’s story right now is powered by a handful of European heavyweights. ASML has been a standout engine, rising strongly and giving the fund a tech-driven tailwind, while SAP has been more of a flat tire, lagging and offsetting some of those gains. On the defensive side, pharma giants like Roche, Novartis, and AstraZeneca have been steadily climbing, adding a smooth, lower-drama boost. Nestlé and Shell are also quietly helping. Overall, it’s a developed Europe play with a noticeable tilt toward health care, financials, and a few key industrial and tech names.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 3.52% | $4.04M | €450.59B | 80.13% | 76 Outperform | |
| Novartis AG | 2.10% | $2.41M | CHF230.97B | 25.96% | 80 Outperform | |
| Roche Holding AG | 2.02% | $2.31M | CHF256.31B | 21.75% | 73 Outperform | |
| AstraZeneca | 1.88% | $2.15M | $295.60B | 19.89% | 80 Outperform | |
| HSBC Holdings | 1.66% | $1.91M | £202.74B | 35.68% | 80 Outperform | |
| Shell (UK) | 1.51% | $1.73M | £189.65B | 27.87% | 73 Outperform | |
| Nestlé SA | 1.39% | $1.60M | CHF204.54B | -0.11% | 71 Outperform | |
| Banco Santander | 1.27% | $1.46M | €139.93B | 57.31% | 73 Outperform | |
| SAP SE | 1.20% | $1.38M | €189.51B | -30.51% | 66 Neutral | |
| Siemens | 1.08% | $1.23M | €167.96B | -4.39% | 74 Outperform |
GSEU Technical Analysis
Negative
―
Price Trends
47.35
Negative
45.68
Negative
43.96
Positive
Market Momentum
-0.61
Positive
29.38
Positive
16.69
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSEU, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 47.56, equal to the 50-day MA of 47.35, and equal to the 200-day MA of 43.96, indicating a neutral trend. The MACD of -0.61 indicates Positive momentum. The RSI at 29.38 is Positive, neither overbought nor oversold. The STOCH value of 16.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GSEU.
GSEU Peer Comparison
Comparison Results
Performance Comparison
GSEU
Goldman Sachs ActiveBeta Europe Equity ETF
45.63
6.76
17.39%
VGK
Vanguard FTSE Europe ETF
―
―
―
SPEU
SPDR Portfolio Europe ETF
―
―
―
DBEU
Xtrackers MSCI Europe Hedged Equity ETF
―
―
―
FEUZ
First Trust Eurozone AlphaDEX ETF
―
―
―
FLEE
Franklin FTSE Europe ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents